Partner Headlines - EXEL

  1. Morning Market Gainers

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Exelixis Data Release Upcoming; Options Activity Spiking

    Benzinga
  4. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  5. 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic ...

    GuruFocus
  6. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  7. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Events for the Week of Nov. 17-21, 2014

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  12. Stocks Hitting 52-Week Lows

    Benzinga
  13. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  14. Midday Losers From Tuesday, September 2

    Benzinga
  15. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  16. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  17. Stocks Hitting 52-Week Lows

    Benzinga
  18. Morning Market Losers

    Benzinga
  19. Benzinga's Top Downgrades

    Benzinga
  20. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  21. Stocks To Watch For September 2, 2014

    Benzinga
  22. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  23. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  24. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  25. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  26. Morning Market Movers

    Benzinga
  27. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  28. Benzinga's Top #PreMarket Gainers

    Benzinga
  29. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  30. Benzinga's Top #PreMarket Gainers

    Benzinga
  31. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  32. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  33. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  34. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  35. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  36. Stocks Hitting 52-Week Lows

    Benzinga
  37. Morning Market Losers

    Benzinga
  38. Benzinga's Top #PreMarket Losers

    Benzinga
  39. Morning Market Movers

    Benzinga
  40. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  41. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  42. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  43. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  44. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  45. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  46. US Stock Futures Up After Upbeat China Data

    Benzinga
  47. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  48. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  49. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  50. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  51. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  52. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  53. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  54. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  55. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  56. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  57. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  58. Health Care Sector Wrap

    FoxBusiness
  59. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  60. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  61. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  62. Exelixis Proposed Offering 20M Shares

    Benzinga
  63. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  64. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  65. Benzinga's Top Pre-Market Gainers

    Benzinga
  66. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  67. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  68. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  69. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  70. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  71. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  72. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  73. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  74. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  75. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  76. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  77. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  78. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  79. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  80. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  81. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  82. Notable Call Options Activity on Exelixis

    Benzinga
  83. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  84. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center